Selected article for: "control group and patient control group"
Author: Atila, Alptug; Alay, Handan; Yaman, Mehmet Emrah; Akman, Tugrul Cagri; Cadirci, Elif; Bayrak, Burak; Celik, Saffet; Atila, Nihal Efe; Yaganoglu, Aycan Mutlu; Kadioglu, Yucel; Halıcı, Zekai; Parlak, Emine; Bayraktutan, Zafer
Title: The serum amino acid profile in COVID-19
  • Cord-id: i4ydtq2d
  • Document date: 2021_10_4
    • ID: i4ydtq2d
    Snippet: The pandemic of the coronavirus disease (COVID-19) caused by SARS-CoV-2 affects millions of people worldwide. There are still many unknown aspects to this infection which affects the whole world. In addition, the potential impacts caused by this infection are still unclear. Amino acid metabolism, in particular, contains significant clues in terms of the development and prevention of many diseases. Therefore, this study aimed to compare amino acid profile of COVID-19 and healthy subject. In this
    Document: The pandemic of the coronavirus disease (COVID-19) caused by SARS-CoV-2 affects millions of people worldwide. There are still many unknown aspects to this infection which affects the whole world. In addition, the potential impacts caused by this infection are still unclear. Amino acid metabolism, in particular, contains significant clues in terms of the development and prevention of many diseases. Therefore, this study aimed to compare amino acid profile of COVID-19 and healthy subject. In this study, the amino acid profiles of patients with asymptomatic, mild, moderate, and severe/critical SARS-CoV-2 infection were scanned with LC–MS/MS. The amino acid profile encompassing 30 amino acids in 142 people including 30 control and 112 COVID-19 patients was examined. 20 amino acids showed significant differences when compared to the control group in COVID-19 patient groups with different levels of severity in the statistical analyses conducted. It was detected that the branched-chain amino acids (BCAAs) changed in correlation with one another, and l-2-aminobutyric acid and l-phenylalanine had biomarker potential for COVID-19. Moreover, it was concluded that l-2-aminobutyric acid could provide prognostic information about the course of the disease. We believe that a new viewpoint will develop regarding the diagnosis, treatment, and prognosis as a result of the evaluation of the serum amino acid profiles of COVID-19 patients. Determining l-phenylalanine and l-2-aminobutyric levels can be used in laboratories as a COVID-19-biomarker. Also, supplementing COVID patients with taurine and BCAAs can be beneficial for treatment protocols. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00726-021-03081-w.

    Search related documents:
    Co phrase search for related documents
    • adaptive immune response and logistic regression analysis: 1
    • adaptive immune response and lung damage: 1, 2, 3, 4, 5, 6
    • adaptive immune response and lymphocyte proliferation: 1, 2
    • adaptive immune response and lymphoid organ: 1
    • adaptive immune response and macrophage monocyte: 1, 2, 3
    • liver damage and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • liver damage and logistic regression analysis: 1, 2
    • liver damage and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • liver damage and macrophage monocyte: 1, 2
    • logistic regression analysis and low albumin level: 1, 2
    • logistic regression analysis and lung damage: 1, 2
    • logistic regression analysis and macrophage monocyte: 1
    • logistic regression and long chain: 1
    • logistic regression and low albumin level: 1, 2, 3, 4
    • logistic regression and lung damage: 1, 2, 3, 4, 5, 6, 7, 8
    • logistic regression and macrophage monocyte: 1
    • lung damage and lymphoid organ: 1
    • lung damage and macrophage monocyte: 1, 2, 3, 4, 5